Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Development and supply agreement signed for dry eye, cystic fibrosis compound
September 15th, 2005
Lantibio, Inc. and Apotex Fermentation Inc. (AFI), announced the signing of an agreement for the development and supply of the lead compound of Lantibio, Moli1901. The molecule is currently in development under two investigational new drug applications (IND) for the treatment of dry eye syndrome and cystic fibrosis. The company expects to commence a phase 2 clinical study with Moli1901 in the third quarter of 2005 in dry eye syndrome. The agreement with AFI, provides access at an attractive price to the drug substance, method development, clinical batches, regulatory support, and supply of commercial batches in exchange for undisclosed...
Source: Women's Health Weekly (2005-09-15)
|
